Crystal structure of encorafenib, C 22 H 27 ClFN 7 O 4 S
Source abstract
Abstract
The crystal structure of encorafenib, C 22 H 27 ClFN 7 O 4 S, has been solved and refined using synchrotron X-ray powder diffraction data, and optimized using density functional theory techniques. Encorafenib crystallizes in space group P 2 1 (#4) with a = 16.17355(25), b = 9.52334(11), c = 17.12368(19) Å, β = 89.9928(22)°, V = 2637.50(4) Å 3 , and Z = 4. The crystal structure consists of alternating layers of stacked halogenated phenyl rings and the other parts of the molecules perpendicular to the a -axis. One molecule participates in two strong N–H⋯N hydrogen bonds (one intra- and the other intermolecular), which are not present for the other molecule. The intermolecular hydrogen bonds link molecule 2 into a spiral chain along the b -axis. The powder pattern has been submitted to ICDD for inclusion in the Powder Diffraction File™ (PDF®).
Source: crossref · Quality: baseline
Research context
OpenAlex topics: X-ray Diffraction in Crystallography · Crystallography and molecular interactions · Pigment Synthesis and Properties
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (32)
Show source-provided references
1. 10.1093/nar/gkaa97110.1093/nar/gkaa971 ↗
2. 10.1107/S090904950801843810.1107/S0909049508018438 ↗
3. 10.3390/ph1408071010.3390/ph14080710 ↗
4. 10.1107/S160057671901409210.1107/S1600576719014092 ↗
5. Etudes sur la loi de Bravais
6. 10.1021/ci049780b10.1021/ci049780b ↗
7. 2020
8. Huang, S. , Jin, X. , Liu, Z. , Poon, D. , Tellew, J. , Wan, Y. , Wang, X. , and Xie, Y. . 2013. “Compounds and Compositions as Protein Kinase Inhibitors.” US Patent 8,501,758 B2.
9. 10.1107/S205252061600395410.1107/S2052520616003954 ↗
10. Bravais · 1866
11. 10.1107/S002188981301311310.1107/S0021889813013113 ↗
12. 10.1017/S088571561400051710.1017/S0885715614000517 ↗
13. 10.1007/BF0054909610.1007/BF00549096 ↗
14. 10.1063/1.296926010.1063/1.2969260 ↗
15. 10.1063/1.46788210.1063/1.467882 ↗
16. Quantum-Mechanical Condensed Matter Simulations with CRYSTAL
17. 10.1097/CCO.000000000000042610.1097/CCO.0000000000000426 ↗
18. 10.3749/canmin.46.5.150110.3749/canmin.46.5.1501 ↗
19. Dassault Systèmes. 2021. Materials Studio. V. 2021. BIOVIA. Windows.
20. 10.1002/jcc.2315310.1002/jcc.23153 ↗
21. Crystalexplorer: A Program for Hirshfeld Surface Analysis, Visualization and Quantitative Analysis of Molecular Crystals10.1107/S1600576721002910 ↗
22. 10.1107/S002188981101462210.1107/S0021889811014622 ↗
23. 10.1016/0927-0256(96)00008-010.1016/0927-0256(96)00008-0 ↗
24. Materials Design. 2016. MedeA. V. 2.20.4. Windows.
25. European Medicines Agency. 2018. “Braftovi.” Assessment Report EMA/CHMP/554696/2018.
26. Materials Data Inc (MDI). 2022. JADE Pro. V. 8.6. Materials Data Inc.
27. 10.1107/S002188981300353110.1107/S0021889813003531 ↗
28. 10.1002/chem.20060095510.1002/chem.200600955 ↗
29. Crystal Impact. 2022. Diamond. V. 4.6.8. Crystal Impact - Dr. H. Putz & Dr. K. Brandenburg. Windows.
30. 10.1107/S205252061402290210.1107/S2052520614022902 ↗
31. A New Law of Crystal Morphology Extending the Law of Bravais
32. The Powder Diffraction File: A Quality Materials Characterization Database10.1017/S0885715619000812 ↗